Friday, October 23, 2020 11:33:32 PM
Senti, I’ve been lurking this board for a couple of years (first invested in 2017, I think) and I’ve always respected the posts from you, Doc, Flipper, Sojourner and even Ex
I do have a question for you - and anyone else who wants to chime in.
Over the past few weeks, the share price appears to be reflecting a greater possibility of success for NWBO. That said, I’m sure a lot of longs on this board would say that the price doesn’t accurately represent their outlook for the company.
I’m generally a pessimistic person but I am very hopeful. We can measure success in many ways, but an easy way is PPS (I use this as I imagine even the most positive data will be spun by some).
With all this in mind, what challenges/risks/obstacles do you think exist that would result in the PPS not increasing after TLD. Obviously a complete failure to meet any of the endpoints would not be ideal, but on a more granular basis, do you ever think about this?
I do have a question for you - and anyone else who wants to chime in.
Over the past few weeks, the share price appears to be reflecting a greater possibility of success for NWBO. That said, I’m sure a lot of longs on this board would say that the price doesn’t accurately represent their outlook for the company.
I’m generally a pessimistic person but I am very hopeful. We can measure success in many ways, but an easy way is PPS (I use this as I imagine even the most positive data will be spun by some).
With all this in mind, what challenges/risks/obstacles do you think exist that would result in the PPS not increasing after TLD. Obviously a complete failure to meet any of the endpoints would not be ideal, but on a more granular basis, do you ever think about this?
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
